The κ opioid receptor (KOR) is one of the promising targets to develop analgesics lacking
morphine like side effects. To seek a novel KOR agonist we designed 6-amide derivatives …

We designed and synthesized the 1, 3, 5-trioxazatriquinane derivatives with m-
hydroxyphenyl groups. These compounds include the phenethylamine structure within them …

We recently reported oxazatricyclodecane derivatives 1 as δ opioid receptor (DOR) agonists
having a novel chemotype, but their DOR agonistic activities were relatively low. Based on …

We synthesized compounds 4a, c–f, h, i containing the oxazatricyclodecane structure from a
novel rearrangement reaction product 2a. All the prepared compounds 4a, c–f, h, i exhibited …

Aminobenzyloxyarylamide derivatives 1a-i and 2a-t were designed and synthesized as
novel selective κ opioid receptor (KOR) antagonists. The benzoyl amide moiety of …

The pharmacology of the delta opioid receptor (DOR) has lagged, mainly due to the lack of
an agonist with high potency and selectivity in vivo. The DOR is now receiving increasing …

A novel 6, 14-epoxymorphinan benzamide derivative (NS22) that was previously reported
showed opioid κ receptor agonistic activity and analgesic activity. The unsatisfactory κ …

The classic “message-address” concept was proposed to address the binding of
endogenous peptides to the opioid receptors and was later successfully applied in the …

Undue central nervous system (CNS) side effects including dysphoria and sedation remain
to be a challenge for the development of κ opioid receptor (KOR) agonists as effective and …

We have reported previously the novel δ opioid agonist KNT-127 which showed high affinity
and selectivity for the δ receptor. Moreover, the analgesic effect of subcutaneously …